| SERES THERAPEUTICS |
| USA |
| Gesundheit |
| US81750R2013 / A413XF |
| 1S90 (Frankfurt) / MCRB (NASDAQ) |
| FRA:1S90, ETR:1S90, 1S90:GR, NASDAQ:MCRB |
| - |
| https://www.serestherapeu.. |
|
Seres Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing live biotherapeutics for serious diseases linked to the human microbiome. Its current work centers on treatments designed to prevent bacterial bloodstream infect..
>Volltext.. |
| 44.09 Mio. EUR |
| 88.03 Mio. EUR |
| 0.99 Mio. EUR |
| -71.88 Mio. EUR |
| -40.67 Mio. EUR |
| -4.35 EUR |
| 69.81 Mio. EUR |
| 25.87 Mio. EUR |
| -36.56 Mio. EUR |
| 1.54 |
| - |
| 36.41% |
| - |
| - |
| - |
| - |
| SERES THERAPEUTICS, SERES THERAPEUTIC |
| 05.08.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|